QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 8/2/183    most recent 15228517-2005-009v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abrey, L. E. Articles by Cairncross, J. G. Search for Related Content PubMed PubMed Citation

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up

Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA (L.E.A., B.H.C., S.D.N., L.M.D.); Northwestern University, Evanston, IL 60201, USA (N.P., L.K.); University of Alabama, Birmingham, AL 35294, USA (S.R., D.S.); New York University, New York, NY 10016, USA (J.L.F., S.G.); Stanford University Medical Center, Stanford, CA 94305, USA (K.P., W.H.); Loyola University Medical Center, Maywood, IL 60153, USA (L.S., R.B.); University of Calgary, Calgary, AB, T2N 1N4, Canada (P.F., D.S.); Kingston Regional Cancer Centre, Kingston, ON, K7L 5P9, Canada (A.M.S.); London Regional Cancer Centre, London, ON N6A 4L6, Canada (D.R.M., D.A.R., J.G.C.); and Albany Medical College, Albany, NY 12208, USA (S.W.)

¹ Address correspondence to Lauren Abrey, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 (abreyl{at}mskcc.org).

We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue. This report summarizes the long-term follow-up of the cohort of 39 patients who received high-dose thiotepa with autologous stem cell support. Thirty-nine patients with a median age of 43 (range, 18-67) and a median KPS of 100 (range, 70-100) were treated. Surviving patients now have a median follow-up of 80.5 months (range, 44-142). The median progression-free survival is 78 months, and median overall survival has not been reached. Eighteen patients (46%) have relapsed. Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse. Persistent nonenhancing tumor at transplant was identified in our initial report as a significant risk factor for relapse; however, long-term follow-up has not confirmed this finding. Long-term neurotoxicity has developed only in those patients whose disease relapsed and required additional therapy; no patient in continuous remission has developed a delayed neurologic injury. This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia.

Key Words: anaplastic • chemotherapy • oligodendroglioma

This article has been cited by other articles:

				J. E. C. Bromberg and M. J. van den Bent Oligodendrogliomas: Molecular Biology and Treatment Oncologist, February 1, 2009; 14(2): 155 - 163. [Abstract] [Full Text] [PDF]

				A. B. Lassman Management of Newly Diagnosed Anaplastic Oligodendrogliomas ASCO Educational Book, January 1, 2009; 2009(1): 85 - 89. [Abstract] [Full Text] [PDF]